• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • OBI Pharma Granted Orphan Drug Designation for ADC Targeted Cancer Therapy americanpharmaceuticalreview
    January 06, 2020
    OBI Pharma announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OBI-999 for the treatment of Pancreatic Cancer. OBI-999 is a first-in-class antibody drug conjugate targeting Globo H, a glycolipid antigen.
  • OBI Pharma granted FDA ODD for OBI-888 biospectrumasia
    November 26, 2018
    OBI Pharma, Inc., a Taiwan, China biopharma company, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OBI-888 for the treatment of Pancreatic Cancer

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service